Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 50

1.

Untargeted Assessment of Tumor Fractions in Plasma for Monitoring and Prognostication from Metastatic Breast Cancer Patients Undergoing Systemic Treatment.

Suppan C, Brcic I, Tiran V, Mueller HD, Posch F, Auer M, Ercan E, Ulz P, Cote RJ, Datar RH, Dandachi N, Heitzer E, Balic M.

Cancers (Basel). 2019 Aug 14;11(8). pii: E1171. doi: 10.3390/cancers11081171.

2.

Multigene methylation analysis of enriched circulating tumor cells associates with poor progression-free survival in metastatic breast cancer patients.

Benezeder T, Tiran V, Treitler AAN, Suppan C, Rossmann C, Stoeger H, Cote RJ, Datar RH, Balic M, Dandachi N.

Oncotarget. 2017 Sep 30;8(54):92483-92496. doi: 10.18632/oncotarget.21426. eCollection 2017 Nov 3.

3.

Microfilter-Based Capture and Release of Viable Circulating Tumor Cells.

Rawal S, Ao Z, Datar RH, Agarwal A.

Methods Mol Biol. 2017;1634:93-105. doi: 10.1007/978-1-4939-7144-2_7.

PMID:
28819843
4.

Interactions between Adipocytes and Breast Cancer Cells Stimulate Cytokine Production and Drive Src/Sox2/miR-302b-Mediated Malignant Progression.

Picon-Ruiz M, Pan C, Drews-Elger K, Jang K, Besser AH, Zhao D, Morata-Tarifa C, Kim M, Ince TA, Azzam DJ, Wander SA, Wang B, Ergonul B, Datar RH, Cote RJ, Howard GA, El-Ashry D, Torné-Poyatos P, Marchal JA, Slingerland JM.

Cancer Res. 2016 Jan 15;76(2):491-504. doi: 10.1158/0008-5472.CAN-15-0927. Epub 2016 Jan 7.

5.

A surface acoustic wave biosensor for interrogation of single tumour cells in microcavities.

Senveli SU, Ao Z, Rawal S, Datar RH, Cote RJ, Tigli O.

Lab Chip. 2016 Jan 7;16(1):163-71. doi: 10.1039/c5lc01212k. Epub 2015 Nov 24.

PMID:
26599306
6.

Identification of Cancer-Associated Fibroblasts in Circulating Blood from Patients with Metastatic Breast Cancer.

Ao Z, Shah SH, Machlin LM, Parajuli R, Miller PC, Rawal S, Williams AJ, Cote RJ, Lippman ME, Datar RH, El-Ashry D.

Cancer Res. 2015 Nov 15;75(22):4681-7. doi: 10.1158/0008-5472.CAN-15-1633. Epub 2015 Oct 15.

7.

Thermoresponsive release of viable microfiltrated Circulating Tumor Cells (CTCs) for precision medicine applications.

Ao Z, Parasido E, Rawal S, Williams A, Schlegel R, Liu S, Albanese C, Cote RJ, Agarwal A, Datar RH.

Lab Chip. 2015 Nov 21;15(22):4277-82. doi: 10.1039/c5lc01024a.

8.

Circulating Tumor Cells: Where From Here?

Datar RH, Balic M, Cote RJ.

Semin Oncol. 2015 Aug;42(4):515-7. doi: 10.1053/j.seminoncol.2015.05.010. Epub 2015 Jun 3. No abstract available.

PMID:
26320056
9.

Highly scalable, uniform, and sensitive biosensors based on top-down indium oxide nanoribbons and electronic enzyme-linked immunosorbent assay.

Aroonyadet N, Wang X, Song Y, Chen H, Cote RJ, Thompson ME, Datar RH, Zhou C.

Nano Lett. 2015 Mar 11;15(3):1943-51. doi: 10.1021/nl5047889. Epub 2015 Feb 5.

PMID:
25636984
10.

Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer.

Goldkorn A, Ely B, Quinn DI, Tangen CM, Fink LM, Xu T, Twardowski P, Van Veldhuizen PJ, Agarwal N, Carducci MA, Monk JP 3rd, Datar RH, Garzotto M, Mack PC, Lara P Jr, Higano CS, Hussain M, Thompson IM Jr, Cote RJ, Vogelzang NJ.

J Clin Oncol. 2014 Apr 10;32(11):1136-42. doi: 10.1200/JCO.2013.51.7417. Epub 2014 Mar 10.

11.

Genetic and epigenetic analysis of putative breast cancer stem cell models.

Balic M, Schwarzenbacher D, Stanzer S, Heitzer E, Auer M, Geigl JB, Cote RJ, Datar RH, Dandachi N.

BMC Cancer. 2013 Jul 24;13:358. doi: 10.1186/1471-2407-13-358.

12.

A novel precision-engineered microfiltration device for capture and characterisation of bladder cancer cells in urine.

Birkhahn M, Mitra AP, Williams AJ, Barr NJ, Skinner EC, Stein JP, Skinner DG, Tai YC, Datar RH, Cote RJ.

Eur J Cancer. 2013 Oct;49(15):3159-68. doi: 10.1016/j.ejca.2013.04.033. Epub 2013 Jul 9.

13.

Combination of molecular alterations and smoking intensity predicts bladder cancer outcome: a report from the Los Angeles Cancer Surveillance Program.

Mitra AP, Castelao JE, Hawes D, Tsao-Wei DD, Jiang X, Shi SR, Datar RH, Skinner EC, Stein JP, Groshen S, Yu MC, Ross RK, Skinner DG, Cortessis VK, Cote RJ.

Cancer. 2013 Feb 15;119(4):756-65. doi: 10.1002/cncr.27763. Epub 2013 Jan 14.

14.

Progress in circulating tumor cell capture and analysis: implications for cancer management.

Balic M, Lin H, Williams A, Datar RH, Cote RJ.

Expert Rev Mol Diagn. 2012 Apr;12(3):303-12. doi: 10.1586/erm.12.12. Review.

15.

Portable filter-based microdevice for detection and characterization of circulating tumor cells.

Lin HK, Zheng S, Williams AJ, Balic M, Groshen S, Scher HI, Fleisher M, Stadler W, Datar RH, Tai YC, Cote RJ.

Clin Cancer Res. 2010 Oct 15;16(20):5011-8. doi: 10.1158/1078-0432.CCR-10-1105. Epub 2010 Sep 28.

16.

Predicting recurrence and progression of noninvasive papillary bladder cancer at initial presentation based on quantitative gene expression profiles.

Birkhahn M, Mitra AP, Williams AJ, Lam G, Ye W, Datar RH, Balic M, Groshen S, Steven KE, Cote RJ.

Eur Urol. 2010 Jan;57(1):12-20. doi: 10.1016/j.eururo.2009.09.013. Epub 2009 Sep 9.

17.

Generation of a concise gene panel for outcome prediction in urinary bladder cancer.

Mitra AP, Pagliarulo V, Yang D, Waldman FM, Datar RH, Skinner DG, Groshen S, Cote RJ.

J Clin Oncol. 2009 Aug 20;27(24):3929-37. doi: 10.1200/JCO.2008.18.5744. Epub 2009 Jul 20.

18.

Unmethylated E-cadherin gene expression is significantly associated with metastatic human prostate cancer cells in bone.

Saha B, Kaur P, Tsao-Wei D, Naritoku WY, Groshen S, Datar RH, Jones LW, Imam SA.

Prostate. 2008 Nov 1;68(15):1681-8. doi: 10.1002/pros.20836.

PMID:
18712716
19.

p53 gene and protein status: the role of p53 alterations in predicting outcome in patients with bladder cancer.

George B, Datar RH, Wu L, Cai J, Patten N, Beil SJ, Groshen S, Stein J, Skinner D, Jones PA, Cote RJ.

J Clin Oncol. 2007 Dec 1;25(34):5352-8.

PMID:
18048815
20.

The role of deoxyribonucleic acid methylation in development, diagnosis, and prognosis of bladder cancer.

Gonzalgo ML, Datar RH, Schoenberg MP, Cote RJ.

Urol Oncol. 2007 May-Jun;25(3):228-35. Review.

PMID:
17483020
21.

Molecular pathways in invasive bladder cancer: new insights into mechanisms, progression, and target identification.

Mitra AP, Datar RH, Cote RJ.

J Clin Oncol. 2006 Dec 10;24(35):5552-64. Review.

PMID:
17158541
22.

Expression of stress response protein Grp78 is associated with the development of castration-resistant prostate cancer.

Pootrakul L, Datar RH, Shi SR, Cai J, Hawes D, Groshen SG, Lee AS, Cote RJ.

Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):5987-93.

23.

Most early disseminated cancer cells detected in bone marrow of breast cancer patients have a putative breast cancer stem cell phenotype.

Balic M, Lin H, Young L, Hawes D, Giuliano A, McNamara G, Datar RH, Cote RJ.

Clin Cancer Res. 2006 Oct 1;12(19):5615-21.

24.

Molecular biology of bladder cancer: prognostic and clinical implications.

Mitra AP, Lin H, Datar RH, Cote RJ.

Clin Genitourin Cancer. 2006 Jun;5(1):67-77. Review.

PMID:
16859582
25.

Cancer immunotherapeutics: raising the ante.

Thorat MA, Datar RH, Joshi NN.

Natl Med J India. 2006 May-Jun;19(3):140-50. Review. No abstract available.

PMID:
16836264
26.

The use of genetic programming in the analysis of quantitative gene expression profiles for identification of nodal status in bladder cancer.

Mitra AP, Almal AA, George B, Fry DW, Lenehan PF, Pagliarulo V, Cote RJ, Datar RH, Worzel WP.

BMC Cancer. 2006 Jun 16;6:159.

27.

Medical applications of nanotechnology.

Lin H, Datar RH.

Natl Med J India. 2006 Jan-Feb;19(1):27-32. Review.

PMID:
16570683
28.

Biomarker profiling for cancer diagnosis, prognosis and therapeutic management.

Mitra AP, Lin H, Cote RJ, Datar RH.

Natl Med J India. 2005 Nov-Dec;18(6):304-12. Review.

PMID:
16483031
29.

Cancer metastasis: advances in the detection and characterization of disseminated tumour cells facilitate clinical translation.

Balic M, Dandachi N, Lin H, Datar RH.

Natl Med J India. 2005 Sep-Oct;18(5):250-5. Review. No abstract available.

PMID:
16433139
30.

Molecular staging of bladder cancer.

Mitra AP, Datar RH, Cote RJ.

BJU Int. 2005 Jul;96(1):7-12. Review.

31.

Promoter hypermethylation: a new therapeutic target emerges in urothelial cancer.

Cote RJ, Laird PW, Datar RH.

J Clin Oncol. 2005 May 1;23(13):2879-81. Epub 2005 Mar 7. No abstract available.

PMID:
15753457
32.

Hyperphosphorylation of pRb: a mechanism for RB tumour suppressor pathway inactivation in bladder cancer.

Chatterjee SJ, George B, Goebell PJ, Alavi-Tafreshi M, Shi SR, Fung YK, Jones PA, Cordon-Cardo C, Datar RH, Cote RJ.

J Pathol. 2004 Jul;203(3):762-70.

PMID:
15221935
33.
34.

Sensitivity and reproducibility of standardized-competitive RT-PCR for transcript quantification and its comparison with real time RT-PCR.

Pagliarulo V, George B, Beil SJ, Groshen S, Laird PW, Cai J, Willey J, Cote RJ, Datar RH.

Mol Cancer. 2004 Jan 23;3:5.

35.

Therapeutic approaches to bladder cancer: identifying targets and mechanisms.

Cote RJ, Datar RH.

Crit Rev Oncol Hematol. 2003 Jun 27;46 Suppl:S67-83. Review.

PMID:
12850529
36.

Role of genetic and expression profiling in pharmacogenomics: the changing face of patient management.

Pagliarulo V, Datar RH, Cote RJ.

Curr Issues Mol Biol. 2002 Oct;4(4):101-10. Review.

37.

Nucleic acids: in the future, in commerce and in the clinical laboratory.

Datar RH.

Natl Med J India. 2001 Nov-Dec;14(6):349-54. Review. No abstract available.

PMID:
11804367
38.

Nucleic acids in therapy.

Datar RH.

Natl Med J India. 2001 Sep-Oct;14(5):290-6. Review.

PMID:
11767224
39.

Bioassay of prostate-specific antigen (PSA) using microcantilevers.

Wu G, Datar RH, Hansen KM, Thundat T, Cote RJ, Majumdar A.

Nat Biotechnol. 2001 Sep;19(9):856-60.

PMID:
11533645
40.

Nucleic acids in disease prognosis.

George B, Cote RJ, Datar RH.

Natl Med J India. 2001 May-Jun;14(3):163-7. Review. No abstract available.

PMID:
11467145
41.

Nucleic acids in diagnosis (Part II): Genetic testing and screening.

Datar RH.

Natl Med J India. 2001 Mar-Apr;14(2):93-8. Review. No abstract available.

PMID:
11396327
42.

Nucleic acids in diagnosis.

Datar RH, Joshi NN.

Natl Med J India. 2001 Jan-Feb;14(1):34-42. Review. No abstract available.

PMID:
11242697
43.

Nucleic acids in disease: information launch-pad.

Datar RH.

Natl Med J India. 2000 Sep-Oct;13(5):255-62. Review. No abstract available.

PMID:
11190056
44.

Analysis of telomerase activity in ovarian cystadenomas, low-malignant-potential tumors, and invasive carcinomas.

Datar RH, Naritoku WY, Li P, Tsao-Wei D, Groshen S, Taylor CR, Imam SA.

Gynecol Oncol. 1999 Sep;74(3):338-45.

PMID:
10479490
45.

Telomerase activity: comparison between fine-needle aspiration and biopsy specimens for the detection of tumor cells.

Naritoku WY, Datar RH, Li P, Groshen SL, Taylor CR, Imam SA.

Cancer. 1999 Aug 25;87(4):210-5.

PMID:
10455209
46.

Telomeric DNA: marker for human prostate cancer development?

Ozen M, Imam SA, Datar RH, Multani AS, Narayanan R, Chung LW, von Eschenbach AC, Pathak S.

Prostate. 1998 Sep 1;36(4):264-71.

PMID:
9719027
47.

Systematic determination of telomerase activity and telomerase length during the progression of human breast cancer in cell culture models.

Imam SA, Kim MS, Anker L, Datar RH, Law RE, Taylor CR.

Anticancer Res. 1997 Nov-Dec;17(6D):4435-41.

PMID:
9494546
48.

Antisense molecular biology.

Datar RH, Ishwad CS, Datar BR, Bishey AN.

Natl Med J India. 1991 Nov-Dec;4(6):275-281. Review. No abstract available.

PMID:
29792006
49.

Antisense RNA therapy for CML--an hypothesis.

Nadkarni KS, Datar RH, Rao SG.

Med Hypotheses. 1991 Aug;35(4):307-10.

PMID:
1943880
50.

A sensitive method for permanent silver staining of DNA in agarose gels.

Datar RH, Bhisey AN.

Indian J Biochem Biophys. 1988 Aug;25(4):373-5. No abstract available.

PMID:
2467875

Supplemental Content

Loading ...
Support Center